Illumina, Inc. (ILMN) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

MIXED

Illumina’s valuation remains higher than Exelixis’s, reflecting market expectations of stronger revenue growth but also a higher risk premium that traders should weigh when allocating capital. The company’s recent sequencing platform sales and regulatory approvals have driven its year‑to‑date outperformance over the broader medical sector, underscoring a robust growth trajectory that could sustain momentum in the next trading week. Meanwhile, Illumina’s progress on the Billion Cell Atlas alliance signals potential acceleration of drug discovery pipelines for partners such as AstraZeneca, though market sentiment remains mixed. The alliance’s mixed reception—AstraZeneca’s share price decline indicating skepticism—creates uncertainty about the immediate commercial impact of the partnership. In the short term, traders should monitor Illumina’s next earnings release for guidance on sequencing platform revenue and any new regulatory approvals that could confirm the growth narrative. Additionally, any announced licensing agreements or milestone achievements within the Billion Cell Atlas initiative will help clarify the partnership’s value proposition. The relative valuation comparison suggests that if Illumina can maintain its growth trajectory, it may justify its premium, but any slowdown could prompt a re‑evaluation of its risk profile. Sector dynamics, such as broader medical stock volatility, could dampen short‑term momentum even as Illumina’s fundamentals remain solid. Finally, keep an eye on any shifts in investor sentiment toward high‑growth biotech names, as changes could influence short‑term liquidity and pricing of Illumina shares.

ILMN|Company Info

Sector

Healthcare

Industry

Diagnostics & Research

Exchange

NMS

Country

United States

Website

illumina.com

Symbol

ILMN

Description

Illumina is a global leader in genetic and genomic analysis, providing comprehensive sequencing and array-based solutions for a diverse customer base. The company's core offering includes instruments, consumables like reagents and flow cells, and various kits designed for whole-genome sequencing, targeted resequencing, and other applications. These products are utilized by a wide range of organizations, including research centers, academic institutions, and healthcare providers, to advance genomic research and diagnostics. Illumina's value proposition lies in its ability to offer cutting-edge tools and services that enable in-depth genetic analysis, contributing to advancements in fields like personalized medicine and disease research. The company distributes its products directly and through distributors, serving customers across the Americas, Europe, Asia Pacific, and other regions.

ILMN|Earnings Snapshot

Earnings Summary

Illumina, a global leader in genetic and genomic analysis, offers sequencing instruments, consumables, and kits that enable research and diagnostics across academia, healthcare, and industry, positioning it within the diagnostics and research sector. In its most recent reported quarter, Q1 2025, the company posted earnings per share of $0.97 versus an estimate of $0.94, marking a modest beat, while revenue reached $1.041 billion; however, comparable data for Q1 2026 and Q2 2026 are not yet available, so a direct comparison of growth acceleration or deceleration cannot be drawn from the current dataset. Historically, Illumina has demonstrated a pattern of revenue growth with occasional EPS misses, but the limited recent data preclude a definitive streak analysis. Recent developments include a partnership with Eli Lilly to launch the Billion Cell Atlas, a large‑scale genomics and AI platform that could open new drug‑target discovery revenue streams, and a German court order to halt supply of certain sequencing systems, which may impose regulatory costs and affect European sales; additionally, institutional activity such as ARK Invest’s divestiture and Leerink Partners’ upgrade to Outperform may influence short‑term sentiment. Going forward, investors should watch for the July 30 earnings release of Q2 2026, where guidance on revenue, EPS, and the impact of the Lilly partnership and the German recall will be disclosed; key will be whether the company can translate the new data platform into incremental revenue and how it manages the regulatory setback. The next quarter’s results will also clarify the trajectory of its core consumables business and any adjustments to its pricing strategy.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.06	-	-
Q1'25	$0.94	$0.97	+3.3%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.1B	-	-
Q1'25	-	$1.0B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

ILMN Stock Snapshot

ILMN is currently trading at $194.09, giving Illumina, Inc. a market cap of 29.37B and a P/E ratio of 34.4. Today's range spans $186.51–$198.00, with shares opening at $197.70 and moving up $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 53/100.

Over the past year ILMN has traded between $88.00 and $199.14 - the current price is +120.6% off the 52-week low and -2.5% from the high. 28 analysts cover the stock with a Buy consensus and a mean 12-month target of $172.53 (range $95.00–$220.00), implying downside of -11.1%.

The bullish case for ILMN is built on complementary signals: 86/100 technical score, BUY designation, and neutral sentiment at 53/100. At $194.09 (near 52-week highs within $88.00–$199.14), the stock is at a capitalization - 29.37B - where active managers can build meaningful positions without moving the market. (P/E: 34.4) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Healthcare.

The combination of a BUY signal (86/100) and neutral news sentiment (53/100) puts ILMN on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 29.37B in Healthcare market cap without immediately moving the stock. At $194.09 (near 52-week highs in the $88.00–$199.14 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.

News Sentiment Analysis

Sentiment gathered from recent headlines

53/100

Strong NegativeNeutralStrong Positive

MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

The article compares Illumina (ILMN) and Exelixis (EXEL) on valuation metrics such as P/E and EV/EBITDA. Illumina trades at higher multiples, reflecting stronger revenue growth expectations. Exelixis offers a more attractive valuation but with slower growth prospects. Investors should weigh the higher risk premium of Illumina against the lower valuation of Exelixis when allocating capital.

What did this article say?

Illumina (ILMN) has posted a year‑to‑date return that outpaces the broader medical sector. The company’s growth is largely driven by increased sales of its genomic sequencing platforms and recent regulatory approvals. Analysts view ILMN’s trajectory as solid, though sector volatility could temper short‑term momentum. Investors should watch how ILMN’s performance aligns with broader medical stock trends.

What did this article say?

Illumina announced progress on the Billion Cell Atlas alliance, a large-scale genomic and CRISPR initiative that supports drug discovery. AstraZeneca, a founding member, benefits from this partnership, potentially accelerating its pipeline. The alliance's progress may enhance future drug development opportunities for both companies. Traders should monitor the alliance's milestones and any subsequent licensing agreements.

What did this article say?

Illumina (ILMN) announced a partnership with Eli Lilly (LLY) as a founding member of the Illumina Billion Cell Atlas. The collaboration will leverage large‑scale genomic data and AI to map disease biology across a wide range of conditions. By integrating Lilly’s drug discovery expertise, the alliance aims to identify novel therapeutic targets more efficiently. The partnership could broaden ILMN’s data platform and open new revenue streams from drug‑target discovery services.

What did this article say?

ARK Invest reduced its Illumina (ILMN) position by selling approximately $39.2 million of shares during the week ended July 17. The sale was part of a broader portfolio rotation that also included cuts in other technology and healthcare names. The move signals a shift in ARK’s allocation strategy rather than a fundamental view on Illumina’s prospects. Investors should monitor Illumina’s upcoming earnings for guidance and watch for any further rebalancing by ARK that could influence the stock’s short‑term trajectory.

What did this article say?

Leerink Partners has upgraded its outlook on Illumina, keeping an Outperform rating while lifting the price target to $210 from $175. The move reflects confidence in the company’s growth prospects and product pipeline. Traders should note the potential upside implied by the higher target and monitor any subsequent earnings or guidance that could validate the bullish stance.

What did this article say?

The German Regional Court of Munich ruled that Illumina and its German subsidiary infringed Element Biosciences patents covering DNA sequencing imaging methods. The court ordered Illumina to halt supply of the affected sequencing systems and consumables in Germany and to recall the infringing products. This ruling imposes legal and financial obligations on Illumina and may influence similar patent disputes elsewhere. The decision raises operational risk for Illumina’s European business and could affect its product pipeline in the region.

What did this article say?

Illumina (ILMN) announced an expansion of its Billion Cell Atlas initiative, adding collaborations with several AI-driven drug development firms. The move aims to accelerate the integration of AI insights into high-throughput cellular profiling, potentially shortening the drug discovery timeline. By leveraging partner expertise, ILMN seeks to enhance data quality and broaden the Atlas’s applicability across therapeutic areas. The announcement underscores ILMN’s commitment to staying at the forefront of precision medicine and AI-enabled research.

What did this article say?

A German court ruled in favor of Element Biosciences, dismissing Illumina’s challenge to a key patent. The decision could limit Illumina’s use of certain sequencing technologies in Europe. This outcome may influence Illumina’s product roadmap and licensing strategy, potentially affecting future revenue streams. Investors should watch for updates in Illumina’s earnings releases and regulatory filings that detail litigation costs and technology licensing adjustments.

What did this article say?

Canaccord Genuity analyst Kyle Mikson maintains a Hold rating on Illumina while raising the price target from $140 to $190. The upgrade reflects optimism about Illumina’s pipeline and expected revenue growth. The firm cites improved product performance and favorable market dynamics as key drivers. Traders should watch the upcoming earnings release and product launch schedule.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

ILMN·Illumina, Inc.

EPS

Revenue

ILMN Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More